Abstract
Fruquintinib(F) is an orally available VEGFR inhibitor that is highly selective for VEGFR-1,2 and 3. In the phase Ⅱ and Ⅲ trials, F has been shown an improved progression-free survival(PFS) compared to placebo and a manageable safety profile with advanced NSCLC. This study aimed to investigate the efficacy and safety of F plus PD-1 inhibitor sintilimab(S) and platinum-based chemotherapy(chemo) as the first-line treatment for advanced naive EGFR- and ALK-negative nsq-NSCLC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
